checkAd
Seagen Aktie
148,94
 
EUR
15.10.21 Tradegate
+1,53 %
+2,24 EUR
Geldkurs 15.10.21
147,38 EUR
40 Stk.
Briefkurs 15.10.21
150,52 EUR
39 Stk.

Seagen Inc. (Nasdaq:SGEN) and Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced that patient enrollment was completed in Cohort K of the phase 1b/2 EV-103 clinical trial (also known as …

Wertpapier:

Seagen Inc. (Nasdaq: SGEN) today announced that it will report its third quarter 2021 financial results on Thursday, October 28, 2021 after the close of U.S. financial markets. Following the announcement, Company management will host a conference …

Wertpapier:

Nachrichten

DatumTitel
28.09.21Seagen Announces Last Patient Enrolled in Phase 2 MOUNTAINEER Trial Evaluating TUKYSA (Tucatinib) Regimen in HER2-Positive Metastatic Colorectal Cancer
Business Wire (engl.) | Weitere Nachrichten
27.09.21Japan’s MHLW Approves PADCEV (enfortumab vedotin) for Advanced Urothelial Cancer
Business Wire (engl.) | Weitere Nachrichten
25.09.21Chartgalerie - Top / Flop Aktien Wochenrückblick Kalenderwoche 38/21
w:o Chartvergleich | Chartanalysen
20.09.21Seagen to Host Conference Call and Webcast Discussion on September 21, 2021 to Discuss TIVDAK (tisotumab vedotin-tftv) Approval
Business Wire (engl.) | Weitere Nachrichten
20.09.21Genmab and Seagen Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Business Wire (engl.) | Weitere Nachrichten
20.09.21Seagen and Genmab Announce FDA Accelerated Approval for TIVDAK (tisotumab vedotin-tftv) in Previously Treated Recurrent or Metastatic Cervical Cancer
Business Wire (engl.) | Weitere Nachrichten
19.09.21Seagen and Genmab Present Interim Results From the innovaTV 205 Study for Tisotumab Vedotin Combination Therapy Treatment of Recurrent or Metastatic Cervical Cancer at ESMO Virtual Congress 2021
Business Wire (engl.) | Weitere Nachrichten
09.09.21Seagen to Present at the Morgan Stanley 19th Annual Global Healthcare Conference
Business Wire (engl.) | Weitere Nachrichten
08.09.21Seagen to Highlight Research From 16 Presentations Across Multiple Tumor Types at ESMO 2021
Business Wire (engl.) | Weitere Nachrichten
04.09.21Chartgalerie - Top / Flop Aktien Wochenrückblick Kalenderwoche 35/21
w:o Chartvergleich | Chartanalysen
09.08.21Seagen and RemeGen Announce Exclusive Worldwide License and Co-Development Agreement for Disitamab Vedotin
Business Wire (engl.) | Weitere Nachrichten
07.08.21Chartgalerie - Top / Flop Aktien Wochenrückblick Kalenderwoche 31/21
w:o Chartvergleich | Chartanalysen
29.07.21Seagen Reports Second Quarter 2021 Financial Results
Business Wire (engl.) | Weitere Nachrichten
09.07.21U.S. FDA Grants Regular Approval and Expands Indication for PADCEV (enfortumab vedotin-ejfv) for Patients with Locally Advanced or Metastatic Urothelial Cancer
Business Wire (engl.) | Weitere Nachrichten
08.07.21Seagen to Host Conference Call and Webcast Discussion of Second Quarter 2021 Financial Results on July 29, 2021
Business Wire (engl.) | Weitere Nachrichten